Author:
Loganayagam A.,Bjarnason I.
Reference72 articles.
1. Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106:287–96.
2. Bernklev T, Jahnsen J, Henriksen M et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:402–12.
3. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007:CD000478.
4. Bjarnason I, Macpherson AJM, Hollander D. Intestinal permeability: an overview. Gastroenterology. 1995;108:1566–81.
5. Bjarnason I, Menzies IS. Causes and consequences of altered gut permeability. In: Brostoff J, Challacombe S, editors. Food Allergy and Intolerance, 2nd edn. London: Saunders, Elsevier Science, 2002:241–57.